MIMEDX GROUP, INC. (NASDAQ:MDXG) Files An 8-K Results of Operations and Financial Condition
Item 2.02
|
Results of Operations and Financial Condition
|
press release announcing its financial results for the year ended
December 31, 2016. The release also announced that executives of
the Company would discuss these results with investors on a
conference call broadcast via the Companys website located at
www.mimedx.com>and provided access information, date and time
for the conference call. A copy of the press release is furnished
herewith as Exhibit 99.1 to this Current Report on Form 8-K and
is incorporated herein by reference.
considered furnished and shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, except as
shall be expressly set forth by specific reference in such
filing.
|
Item 9.01
|
Financial Statements and Exhibits
|
|
(c)
|
Exhibits
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
MiMedx Group, Inc. Press Release, dated February 23,
2017 |
About MIMEDX GROUP, INC. (NASDAQ:MDXG)
MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts. MIMEDX GROUP, INC. (NASDAQ:MDXG) Recent Trading Information
MIMEDX GROUP, INC. (NASDAQ:MDXG) closed its last trading session down -0.34 at 7.95 with 599,676 shares trading hands.
